Effects of Qingshen Granules on Immune Function in Patients with Comorbid Chronic Renal Failure and Damp-Heat Syndrome: A Multicenter, Randomized, Controlled Trial

Author:

Wang Dong1ORCID,Wang Yiping1ORCID,Li Chuanping2,Liu Shifu3,Zhang Lei1,Jin Hua1

Affiliation:

1. Department of Nephrology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China

2. Department of Nephrology, Lu’an Hospital of Traditional Chinese Medicine, Lu’an 237006, China

3. Department of Nephrology, Wuhu Hospital of Traditional Chinese Medicine, Wuhu 241000, China

Abstract

Objective. The current study sought to compare the effects of the addition of Qingshen granules to conventional Western medicine on immune function in patients with comorbid chronic renal failure and damp-heat syndrome and to explore the possible mechanisms responsible for any differences observed. Methods. Through a multicenter, randomized, controlled study, a total of 282 eligible patients were divided into experimental (n = 136) and control groups (n = 146). All of the patients were treated with conventional Western medical therapy. The experimental group also received Qingshen granules three times daily for 12 weeks. Clinical efficacy was observed in the two groups. Peripheral blood levels of CD4+ T cells, CD8+ T cells, Th17 cells, nuclear factor-κB p65 (NF-κB p65) activity, serum interleukin-17 (IL-17), serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), tumor necrosis factor receptor-associated factor 6 (TRAF6), fibronectin (FN), and type IV collagen (Col-IV) were detected in both groups. Results. The total clinical curative effective rate was significantly higher p < 0.05 in the experimental group (79.41%) than in the control group (67.12%). Before treatment, there were no significant differences in CD4+/CD8+ T cell ratio, Th17 cell level, NF-κB p65 activity, serum IL-17, IL-6, TNF-α, TRAF6, FN, and Col-IV between the experimental and control groups p > 0.05 ; however, all of the measures were significantly higher than those observed in a healthy comparison group ( p < 0.05 or p < 0.01 ). After treatment, the above indexes in the experimental group were significantly lower than those before treatment ( p < 0.05 or p < 0.01 ). Similarly, NF-κB p65 activity, serum IL-17, TNF-α, TRAF6, FN, and Col-IV in the control group were significantly lower than the levels observed prior to treatment ( p < 0.05 or p < 0.01 ); however, while all of the other indexes were lower than those observed before treatment, the differences were not statistically significant p > 0.05 . Conclusion. Qingshen granules adjust immune dysfunction, improve immunity mediated inflammatory response, and attenuate renal fibrosis in patients with comorbid chronic renal failure and damp-heat syndrome.

Funder

Scientific and Technological Research Plan of Anhui Province

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

Reference28 articles.

1. Meta analysis and comparison of the prevalence of chronic kidney disease in Chinese adult;S. Wang;Chinese Journal of Nephrology,2018

2. Study on the distribution and evolution of TCM Syndromes of chronic kidney disease;K. Gao;Jiangsu Traditional Chinese Medicine,2008

3. Effect of Qingshen granule on immune inflammation in patients with chronic renal failure with damp heat syndrome;Y. Wang;Chinese Journal of Integrated Traditional and Western Medicine,2016

4. Effect of Qingshen Granule on NF-κB signal pathway in patients with chronic renal failure of damp heat syndrome;D. Wang;Chinese Journal of Integrated Traditional and Western Medicine,2017

5. The prognostic value of oxidative stress and inflammation in Chinese hemodialysis patients

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3